Morgan Stanley estimates around 3% FY23 EPS accretion from the decision by Integral Diagnostics to acquire Horizon Radiology in New Zealand for -$27.4m, with an earn-out of up to $2.7m over two years.

Nonetheless, the broker is looking for a volume recovery in the existing business before lifting its rating from Equal-weight. The $4.36 target price is also unchanged. Industry view: In line.

Sector: Health Care Equipment & Services.

Target price is $4.36.Current Price is $3.68. Difference: $0.68 - (brackets indicate current price is over target). If IDX meets the Morgan Stanley target it will return approximately 16% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2022 Acquisdata Pty Ltd., source FN Arena